(EN) The invention is directed to mosaic human immunodeficiency virus HIV-1 envelopes, and methods of using the same to induce Antibody (Ab)-dependent cellular cytotoxicity (ADCC) responses. Specifically, the disclosure provides new mosaic HIV-1 envelope designs, selection of HIV-1 envelopes and combinations thereof; methods of using these envelopes to induce antibody protective responses, wherein the protective responses are associated with ADCC activity. Further provided are mosaic HIV-1 envelope sequences, and a pharmaceutical composition comprising a polypeptide of any one of the envelopes or a nucleic acid encoding any one of the envelopes disclosed.
(FR) La présente invention concerne des enveloppes mosaïques du VIH-1, et des méthodes d'utilisation de celles-ci pour induire des réponses d'ADCC.